Abstract
This extension study will allow participants that completed Study HGT-HIT-094 to continue
receiving Elaprase treatment in conjunction with idursulfase IT or to continue receiving
Elaprase treatment and begin concurrent IT treatment for those that did not receive
idursulfase IT treatment in Study HGT-HIT-094.

